ino-3112
Vaccineexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2014 (NCT02172911)
Timeline
Indications
Studied for
- Carcinoma · Phase 2
- Carcinoma, Squamous Cell · Phase 2
- Human papillomavirus 16 · Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 2
- Oropharyngeal Neoplasms · Phase 2
- Papillomavirus Infections · Phase 2
- Penile Neoplasms · Phase 2
- Rectal Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 2
- Vaginal Neoplasms · Phase 2
- Vulvar Neoplasms · Phase 2
Mechanism of action
- Human papillomavirusImmunity, active
Human papillomavirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ino-3112
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04001413 | Phase 2 | Jul 31, 2019 | AstraZeneca, Johns Hopkins University |
| NCT03439085 | Phase 2 | Sep 30, 2018 | AstraZeneca, Inovio Pharmaceuticals, University of Texas at Houston |
| NCT02501278 | Phase 2 | May 1, 2016 | European Organisation for Research and Treatment of Cancer, Inovio Pharmaceuticals, University of Lausanne |
| NCT02172911 | Phase 1/Phase 2 (Phase 2) | May 1, 2014 | Inovio Pharmaceuticals |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Inovio Pharmaceuticals | For profit | 3 | 1 | 1 | 2014 |
| AstraZeneca | For profit | 2 | 0 | 1 | 2018 |
| European Organisation for Research and Treatment of Cancer | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Lausanne | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2018 |
6 organizations
Page 1 / 1